Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 7th Annual Conference on Stem Cell and Regenerative Medicine Manchester , UK.

Day 1 :

OMICS International Stem Cell Congress 2016 International Conference Keynote Speaker Barritault Denis photo

Denis Barritault has graduated in Physics and completed his PhD in Biochemistry from Paris University, France. He has received his Postdoctoral studies in Molecular Immunology at Pasteur Institute and NYU and as NIH Fogarty Fellow he has joined INSERM unit in Paris as Developmental Biologist. He made the first description and patents of FGF extracted from retina in 1979 and 1982 as skin and cornea healing agent and became full Professor at Paris-Est University in 1985. He has also Founded and Directed a CNRS Laboratory on cell and tissue regeneration until 2003. He is currently a President of OTR3, Emeritus Professor,Honorary Director of CRRET CNRS unit and is the author in over 200 publications and 30 patents.


Heparan sulfates (HS) are key elements of the extracellular matrix (ECM), which store and protect various cell communication peptides (CCP). HS play a central role in tissue homeostasis, by modulating the bioavailability of CCP hence controlling the cell migration and differentiation required for healing processes. Tissue injury will lead to destruction of cells and surrounding ECM is destroyed. CCPs synthesized by inflammatory and circulating cells can then promote tissue repair but with a loss of tissue quality, leaving scars or fibroses. We have engineered biodegradable nano-polymers mimicking the HS. They bind to the structure proteins of the damaged ECM and to the CCP produced by healthy neighboring cells, thereby restoring the ECM microenvironment and tissue homeostasis. This matrix therapy approach has considerably improved the quality of healing in various animal models with reduction or absence of fibrosis resulting in a real regeneration process. These HS mimetics have therefore been named RGTA, for ReGeneraTing Agents. The RGTA technology has been validated in over 80 published preclinical studies and is now marketed as a human healing agent both for corneal and skin ulcers. RGTA are in development for more tissue injuries including mucosis, tendon and muscle. Altogether this study underline the potential of RGTAs as a new therapeutic class in the field of regenerative medicine, simple safe and exploiting our natural potential without need for exogenous cells supply but can combine with cell therapy to restore cellular microenvironment and favor homing.

Keynote Forum

Y James Kang

Sichuan University, China

Keynote: Rejuvenation therapy for ischemic heart disease

Time : 10:00-10:25

OMICS International Stem Cell Congress 2016 International Conference Keynote Speaker Y James Kang photo

Y James Kang is currently a Professor and Director of the Regenerative Medicine Research Center at Sichuan University West China Medical College, the President and CEO of Sichuan 3D Bio-printing Institute, the Director of Sichuan Regenerative Medicine Research and Technology Center, the Editor-in-Chief of the journals Cardiovascular Toxicology and Regenerative Medicine Research and the Editor of the book series of Methods in Pharmacology and Toxicology. Prior to his current positions, he was a Professor and Distinguished University Scholar at University of Louisville, USA (1996-2009). He was elected as a Fellow to the Academy of Toxicological Sciences in 2001. His research interests are in regenerative medicine, focusing on 3D bio-printing and cardiovascular regeneration as well as dietary manipulation of cardiovascular disease, liver fibrosis and cirrhosis, oxidative stress and antioxidant mechanisms and non-human primate models
for human diseases.


Cell-based therapy for ischemic heart disease holds a promise for the management of the disease condition. However, controversies regarding the eventually clinical benefits often arise from experimental and clinical studies. Unmatched conditions between experimental animal studies and clinical trials and the distinction between acute and chronic heart disease are major attributable factors to the controversies. Most experimental studies are carried out in young and healthy animals but clinical patients are often elders with multiple complications. Under acute ischemic heart disease conditions, freshly injured heart tissue may retain the potential for recovery. But under chronic conditions, the progressively deteriorative milieu dampens the repair mechanism, eliminating the tissue injury signals and diminishing the rejuvenation capacity. Therefore, reestablishing tissue injury signaling system and remobilizing the rejuvenation capacity would greatly enhance the efficacy of cell-based therapy for ischemic heart disease. To achieve this goal, we developed an approach to activate the tissue injury signaling system in the cardiac ischemic infarct tissue of Rhesus monkeys, reestablishing mesenchymal stem cell homing process and reacting myocardial repair mechanism. This approach, in combination with our recently established 3D bio-printing program, significantly improved the disease condition of heart failure in monkey model of myocardial ischemic infarction.

Keynote Forum

Taihua Wang

Interventional Hospital of Shandong Red Cross Society and Cell Biotechnology Co. Ltd, China

Keynote: Significant physical function improvements of 3 serious injured patients after neural stem cell therapy

Time : 10:25-10:55

OMICS International Stem Cell Congress 2016 International Conference Keynote Speaker Taihua Wang photo

Taihua Wang has completed his MD in 1983 from Shandong Medical University and obtained his Postdoctoral studies in Danish Royal Hospital from 1990 to 1993.He is the Director of Interventional Hospital of Shandong Red Cross Society, one of the top hospitals in China. He has published more than 20 papers in reputed journals and was awarded 7 national patents. He is pioneer of stem cell therapy in the world and has extensive collaborations with Harvard Medical School, University of Pennsylvania, etc. He has already performed several thousand clinical cases with  during the past 12 years.


Here, we reported three patient cases in which they were seriously injured by accidents. Among them, two of them were injured by car accidents and the third patient was injured by falling down from Chinese house roof approximate 3 meter high, respectively. The common symptoms of them are head and chest vertebral injury, coma and incontinence of feces and pee, numbness of lower limb and disabled or restricted movement and so forth. After regular treatments at hospitals for different periods, all of them only obtained minor function recoveries. After subsequent 2 or 3 courses of treatment with neural stem cells, significant physical function improvements were successfully achieved. These functional recoveries included feeling strong waist, sitting up freely but cannot stand, perceiving feces and pee but cannot control, the left leg can move horizontally but cannot lift up, the right leg can lift up but cannot resist the resistance, higher double lower limb muscle tensions, having feeling obstacle under xiphoid process and the double arms can move freely, etc. More importantly, after stem
cell transplantation therapy, one of them, could crawl and even could walk with the help of walking aid. These preliminary clinical trials vividly demonstrated that the feasibility of stem cell therapy for the patients with serious brain and spinal cord injuries and provided pioneer evidences for further clinical trials with various stem cells to treat different human diseases.